- Home
- / Acceleron Pharma
Acceleron Pharma
Revenue
$92.5 M
FY, 2020
Acceleron Pharma Summary
Company Summary
- Overview
- Acceleron Pharma is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of treatments for hematologic, neuromuscular, and pulmonary diseases. The company specializes in TGF-beta biology and protein engineering to regulate cellular growth and repair.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2003
- HQ
- Cambridge, MA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Kevin McLaughlin, Senior Vice President and Chief Financial Officer
Jay T. Backstrom, Executive Vice President, Head of Research and Development
James Desiderio, Senior Vice President, Regulatory and Quality
Operating MetricsView all
Patent Applications
637
26.1%
FY, 2019
Patents Issued
788
11.3%
FY, 2019
LocationsView all
2 locations detected
Cambridge, MA HQ
United States
128 Sidney St
Zug, ZG
Switzerland
Grafenauweg 8
Acceleron Pharma Financials
Summary Financials
- Revenue (Q3, 2021)
- $34.2M
- Net income (Q3, 2021)
- ($70.5M)
- Cash (Q3, 2021)
- $336.5M
- EBIT (Q3, 2021)
- ($70.6M)